BR0205449A - composições farmacêuticas de peptìdeos, secretados pelas glándulas do veneno de serpentes, particurlamente da bothrops jararaca, inibidores de vasopeptidases, evasins, seus análogos, derivaados e produtos associados para o desenvolvimento de aplicações e uso em doenças crÈnico-degenerativas - Google Patents
composições farmacêuticas de peptìdeos, secretados pelas glándulas do veneno de serpentes, particurlamente da bothrops jararaca, inibidores de vasopeptidases, evasins, seus análogos, derivaados e produtos associados para o desenvolvimento de aplicações e uso em doenças crÈnico-degenerativasInfo
- Publication number
- BR0205449A BR0205449A BRPI0205449-3A BR0205449A BR0205449A BR 0205449 A BR0205449 A BR 0205449A BR 0205449 A BR0205449 A BR 0205449A BR 0205449 A BR0205449 A BR 0205449A
- Authority
- BR
- Brazil
- Prior art keywords
- analogs
- evasins
- derivatives
- applications
- chronic degenerative
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 229920003360 EVASIN® Polymers 0.000 title abstract 4
- 230000001684 chronic effect Effects 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 241000271517 Bothrops jararaca Species 0.000 title abstract 2
- 210000004907 gland Anatomy 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000003998 snake venom Substances 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 3
- 229920002988 biodegradable polymer Polymers 0.000 abstract 2
- 239000004621 biodegradable polymer Substances 0.000 abstract 2
- 229940097362 cyclodextrins Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 102400000345 Angiotensin-2 Human genes 0.000 abstract 1
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 1
- 101800004538 Bradykinin Proteins 0.000 abstract 1
- 102400000967 Bradykinin Human genes 0.000 abstract 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 241000270295 Serpentes Species 0.000 abstract 1
- 229950006323 angiotensin ii Drugs 0.000 abstract 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0205449-3A BR0205449A (pt) | 2002-12-09 | 2002-12-09 | composições farmacêuticas de peptìdeos, secretados pelas glándulas do veneno de serpentes, particurlamente da bothrops jararaca, inibidores de vasopeptidases, evasins, seus análogos, derivaados e produtos associados para o desenvolvimento de aplicações e uso em doenças crÈnico-degenerativas |
| US10/537,264 US20080199503A1 (en) | 2002-12-09 | 2003-12-09 | Pharmaceutical Compositions Preparation of Peptides, Secreted by the Snake Venom Glands, Particularly of Bothrops Jararaca, Vasopeptidases Inhibitors, Evasins, Their Analogues, Derivatives and Products Associated, Thereof, for Development of Applications and Use in Chronic-Degenerative Diseases |
| CN2003801081877A CN1820018B (zh) | 2002-12-09 | 2003-12-09 | 由蛇毒腺分泌的肽的药物组合物制剂 |
| MXPA05006170A MXPA05006170A (es) | 2002-12-09 | 2003-12-09 | Preparacion de peptidos secretados por las glandulas de veneno de serpientes, para composiciones farmaceuticas. |
| EP03812538A EP1581550A2 (en) | 2002-12-09 | 2003-12-09 | Pharmaceutical compositions preparation of peptides, secreted by the snake venom glands, particulary of bothrops jararaca, vasopeptidases inhibitors, evasins, their analogues, derivatives and products associated, thereof. for development of aplications and use in chronic-degenerative diseases |
| PCT/BR2003/000192 WO2004052273A2 (en) | 2002-12-09 | 2003-12-09 | Pharmaceutical compositions preparation of peptides, secreted by the snake venom glands |
| CA002507980A CA2507980A1 (en) | 2002-12-09 | 2003-12-09 | Pharmaceutical compositions preparation of peptides, secreted by the snake venom glands |
| JP2004557689A JP2006517520A (ja) | 2002-12-09 | 2003-12-09 | 蛇、特にジャララカの毒腺から分泌されたペプチド類、バソぺプチダーゼ阻害薬、ｅｖａｓｉｎ類、それらの類似体および誘導体からなる薬学組成物の製造法、および用途開発のための関連製品および晩成退行性疾病での使用 |
| AU2003302871A AU2003302871A1 (en) | 2002-12-09 | 2003-12-09 | Pharmaceutical compositions preparation of peptides, secreted by the snake venom glands |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0205449-3A BR0205449A (pt) | 2002-12-09 | 2002-12-09 | composições farmacêuticas de peptìdeos, secretados pelas glándulas do veneno de serpentes, particurlamente da bothrops jararaca, inibidores de vasopeptidases, evasins, seus análogos, derivaados e produtos associados para o desenvolvimento de aplicações e uso em doenças crÈnico-degenerativas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0205449A true BR0205449A (pt) | 2006-03-07 |
Family
ID=32476825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0205449-3A BR0205449A (pt) | 2002-12-09 | 2002-12-09 | composições farmacêuticas de peptìdeos, secretados pelas glándulas do veneno de serpentes, particurlamente da bothrops jararaca, inibidores de vasopeptidases, evasins, seus análogos, derivaados e produtos associados para o desenvolvimento de aplicações e uso em doenças crÈnico-degenerativas |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080199503A1 (https=) |
| EP (1) | EP1581550A2 (https=) |
| JP (1) | JP2006517520A (https=) |
| CN (1) | CN1820018B (https=) |
| AU (1) | AU2003302871A1 (https=) |
| BR (1) | BR0205449A (https=) |
| CA (1) | CA2507980A1 (https=) |
| MX (1) | MXPA05006170A (https=) |
| WO (1) | WO2004052273A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100184708A1 (en) * | 2007-09-11 | 2010-07-22 | Dorian Bevec | Use of gly-pro-glu-oh (gpe) as a therapeutic agent |
| US9993793B2 (en) | 2010-04-28 | 2018-06-12 | The Procter & Gamble Company | Delivery particles |
| US9186642B2 (en) | 2010-04-28 | 2015-11-17 | The Procter & Gamble Company | Delivery particle |
| WO2012138710A2 (en) | 2011-04-07 | 2012-10-11 | The Procter & Gamble Company | Personal cleansing compositions with increased deposition of polyacrylate microcapsules |
| WO2012138696A2 (en) | 2011-04-07 | 2012-10-11 | The Procter & Gamble Company | Shampoo compositions with increased deposition of polyacrylate microcapsules |
| WO2012138690A2 (en) | 2011-04-07 | 2012-10-11 | The Procter & Gamble Company | Conditioner compositions with increased deposition of polyacrylate microcapsules |
| US12486478B2 (en) | 2020-10-16 | 2025-12-02 | The Procter & Gamble Company | Consumer products comprising delivery particles with high core:wall ratios |
| US12227720B2 (en) | 2020-10-16 | 2025-02-18 | The Procter & Gamble Company | Consumer product compositions with at least two encapsulate populations |
| CN116323893A (zh) | 2020-10-16 | 2023-06-23 | 宝洁公司 | 包含包封物群体的消费产品组合物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0101088A (pt) * | 2001-03-19 | 2003-03-18 | Biolab Sanus Farmaceutica Ltda | Processo de isolamento e purificação de peptìdeos inibidores das vasopeptidases, com especificidade para o sìtio carboxìlico da enzima conversora da angiotensina, secretados pelas glândulas do veneno de serpentes (bpps), particularmente bothrops jararaca, ou produzidos endogenamente (evasins) possuindo ação vasodilatadora e anti-hipertensiva; processo de determinação da sequência de amido-ácidos dos peptìdios inibidores secretados pela glândula de veneno de serpentes (bpps) ou endógenos (evasins); processo de determinação da sequência de aminoácidos dos bpps por dedução do cdna dos precursores dessas moléculas expressos em tecidos de serpentes, especificamente bothrops jararaca. processo de determinação da sequência de aminoácidos dos evasins por dedução do cdna dos precursores dessas moléculas expressos em tecidos de serpentes, especificamente bothrops jararaca, processo de amplificação do cdna a partir das bibliotecas de cdna de pâncreas e/ou cérebro de serpentes, especificamente bothrops jararaca; processo de sìntese em fase sólida de peptìdeos inibidores das vasopeptidases com ação vasodilatadora e anti-hipertensiva, peptìdeos inibidores das vasopeptidases com ação anti-hipertensiva; utilização dos peptìdeos inibidores das vaso peptidases com ação vasodilatadora e anti-hipertensiva na obtenção de composições farmacêuticas; processo de determinação da atividade inibitória sobre as vasopeptidases e de atividade biológica sobre músculo liso, sistema cardiovascular e microcirculatório. |
-
2002
- 2002-12-09 BR BRPI0205449-3A patent/BR0205449A/pt not_active IP Right Cessation
-
2003
- 2003-12-09 EP EP03812538A patent/EP1581550A2/en not_active Withdrawn
- 2003-12-09 CA CA002507980A patent/CA2507980A1/en not_active Abandoned
- 2003-12-09 US US10/537,264 patent/US20080199503A1/en not_active Abandoned
- 2003-12-09 CN CN2003801081877A patent/CN1820018B/zh not_active Expired - Fee Related
- 2003-12-09 JP JP2004557689A patent/JP2006517520A/ja active Pending
- 2003-12-09 MX MXPA05006170A patent/MXPA05006170A/es unknown
- 2003-12-09 WO PCT/BR2003/000192 patent/WO2004052273A2/en not_active Ceased
- 2003-12-09 AU AU2003302871A patent/AU2003302871A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004052273A3 (en) | 2005-04-21 |
| AU2003302871A1 (en) | 2004-06-30 |
| MXPA05006170A (es) | 2005-08-26 |
| WO2004052273A2 (en) | 2004-06-24 |
| JP2006517520A (ja) | 2006-07-27 |
| CN1820018B (zh) | 2011-11-16 |
| CN1820018A (zh) | 2006-08-16 |
| EP1581550A2 (en) | 2005-10-05 |
| US20080199503A1 (en) | 2008-08-21 |
| AU2003302871A8 (en) | 2004-06-30 |
| CA2507980A1 (en) | 2004-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0314943A (pt) | Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes | |
| WO1997049373A3 (en) | Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin | |
| BR9911072A (pt) | Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior | |
| BR9911488A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| ES2054501T3 (es) | Procedimiento para la fabricacion de ramnosa a partir de ramnolipidos. | |
| BR9916732A (pt) | Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa) | |
| BR0313041A (pt) | Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos | |
| BR0314071A (pt) | Derivados de pró-droga de 1,3-diamino-2-hidroxipropano | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| BR0317463A (pt) | Métodos de triar para um composto que evita ou reduz a dissolução de um tetrâmero de transtiretina e de tratar uma doença amilóide transtiretina | |
| BR0315720A (pt) | Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário | |
| BR0113927A (pt) | Processos para retardar a recorrência dos sintomas de herpes vìrus | |
| BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
| BR0313060A (pt) | Composições farmacêuticas aquosas de 2,6-diisopropilfenol | |
| EP1819227A4 (en) | PHARMACEUTICAL FORMULATIONS OF DECITABIN | |
| BR9803300A (pt) | Formulação farmacêutica. | |
| BRPI0114344B8 (pt) | composto retinóide, seu uso, sua composição farmacêutica e seu processo de preparação | |
| BR0205449A (pt) | composições farmacêuticas de peptìdeos, secretados pelas glándulas do veneno de serpentes, particurlamente da bothrops jararaca, inibidores de vasopeptidases, evasins, seus análogos, derivaados e produtos associados para o desenvolvimento de aplicações e uso em doenças crÈnico-degenerativas | |
| BR0112337A (pt) | Derivados de fosfolipìdeos de ácido valpróico e suas misturas | |
| BR0015939A (pt) | Sistemas terapêuticos transdérmicos com estabilidade aperfeiçoada e um processo para a sua preparação | |
| BRPI9910445B8 (pt) | preparação farmacêutica na forma de comprimido, bem como seu processo de produção | |
| BR0009476A (pt) | Esteróides imunomoduladores, em particular hemidrato de 16 alfa-bromoepiandrosterona | |
| HUP0301506A2 (hu) | Gyógyászati készítmények nedves hámfelületek fájdalmas, gyulladásos vagy fekélyes állapotai, így például nyálkahártyagyulladás, szájgyulladás és behcet-tünetcsoport kezelésére | |
| AR004502A1 (es) | Una asociacion trisecuencial hormonal, estroprogestativa, su utilizacion y un procedimiento para su preparacion | |
| BR0015423A (pt) | Análogos de ácido 15-hidroxieicosatetraenóico interrompidos por heteroátomo e métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15G | Petition not considered as such [chapter 15.7 patent gazette] |
Free format text: NAO CONHECIDA AS PETICOES NO 068462/RJ DE 09/12/2003, NO 020050080357/RJ DE 11/08/2005 E NO020080087774 DE 23/06/2008 EM VIRTUDE DO DISPOSTO NO ART. 219, 2O DA LPI. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 7A. E 8A. ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011. |